Lilly Cialis Delay Clears Space For Bayer Nuviva: Extra FDA Caution Cited

The delay in the FDA review of Lilly/Icos' Cialis creates an opening for Bayer to establish Nuviva as the primary challenger to Pfizer's Viagra in the oral erectile dysfunction class